Page last updated: 2024-12-07

enkephalin, met(2)-pronh2(5)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID123894
CHEMBL ID4095111
SCHEMBL ID11065220
MeSH IDM0076979

Synonyms (20)

Synonym
enkephalin, methionyl(2)-prolinamide(5)-
d-met(2)-pro(5)-enkephalinamide
l-tyrosyl-d-methionylglycyl-l-phenylalanyl-l-prolinamide
2-met-5-pronh2-enkephalin
l-prolinamide, l-tyrosyl-d-methionylglycyl-l-phenylalanyl-
gyki 14238
enkephalin, met(2)-pronh2(5)-
d-met(sup 2)pro(sup 5)-enkephalinamide
63307-63-1
(2s)-1-[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxamide
tyr-d-met-gly-phe-pro-nh2
SCHEMBL11065220
1-[n-(2-{[2-{[2-amino-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-1-hydroxy-4-(methylsulfanyl)butylidene]amino}-1-hydroxyethylidene)phenylalanyl]pyrrolidine-2-carboximidic acid
DTXSID80979407
CHEMBL4095111 ,
bdbm50233414
[d-met2,pro5]-enkephalinamide
CS-0615618
(d-met2,pro5)-enkephalinamide
HY-P3547

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Glycosylation by simple sugars is a drug discovery alternative that has been explored with varying success for enhancing the potency and bioavailability of opioid peptides."( Role of the sugar moiety on the opioid receptor binding and conformation of a series of enkephalin neoglycopeptides.
Arévalo, JC; Arsequell, G; Barreto-Valer, K; Calle, LP; Gonzalez-Nunez, V; Jiménez-Barbero, J; Marcelo, F; Rodríguez, RE; Rosa, M; Sánchez-Sánchez, J; Valencia, G, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" The enkephalin dose-response line was shifted to the right, considered a sign of the development of cross-tolerance."( Oxytocin blocks the development of heroin-enkephalin cross-tolerance in mice.
Kovács, GL; Kriván, M; Sarnyai, Z; Szabó, G; Telegdy, G, 1992
)
0.28
" The serum prolactin level increased dose-dependently, while the growth hormone (HGH) content showed biphasic dose-response pattern."( Human tolerability studies with D-Met2,Pro5-enkephalinamide.
Borvendég, J; Földes, J; Gara, A; Karczag, I; Marosfi, S; Rónai, AZ; Székely, JI; Tolna, J; Török, K; Váradi, A, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Opioid receptor, delta 1b Danio rerio (zebrafish)Ki0.25640.04500.47591.4270AID1432897
Opioid receptor homologueDanio rerio (zebrafish)Ki0.56580.07300.28730.5658AID1432896
Mu-type opioid receptorDanio rerio (zebrafish)Ki0.26900.18700.52891.3170AID1432895
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1432897Displacement of [3H]DPN from zebrafish delta 1b opioid receptor expressed in HEK293 cell membranes after 4 hrs by scintillation counting method2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Role of the sugar moiety on the opioid receptor binding and conformation of a series of enkephalin neoglycopeptides.
AID1432896Displacement of [3H]DPN from zebrafish delta 1a opioid receptor expressed in HEK293 cell membranes after 1 hr by scintillation counting method2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Role of the sugar moiety on the opioid receptor binding and conformation of a series of enkephalin neoglycopeptides.
AID1432895Displacement of [3H]DPN from zebrafish mu opioid receptor expressed in HEK293 cell membranes after 1 hr by scintillation counting method2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
Role of the sugar moiety on the opioid receptor binding and conformation of a series of enkephalin neoglycopeptides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-199039 (61.90)18.7374
1990's19 (30.16)18.2507
2000's4 (6.35)29.6817
2010's1 (1.59)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.87 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index4.06 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.54%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other64 (98.46%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]